Migraine Science
Complete Guide to Neuromodulation Devices for Migraine Treatment
Posted on May 09 2025,
Stay in the Loop on the Latest in Migraine:
Neuromodulation Devices for Migraine Treatment
A comparison of neuromodulation techniques for migraine management, with information for both patients and healthcare providers.
| Device/Technique | Image | Type | Target & Mechanism | Treatment Protocol | Efficacy for Migraine | Level of Evidence | Common Side Effects |
|---|---|---|---|---|---|---|---|
|
Transcutaneous Supraorbital Nerve Stimulation (t-SNS/e-TNS) Cefaly® and HeadaTerm® |
 |
Non-invasive Wearable device |
Stimulates branches of the ophthalmic nerve in the forehead through a small electrode. Acts like a specialized TENS unit that modulates pain signals from trigeminal pathways. | Prevention: 20-minute daily sessions, preferably in the evening; max intensity 16 mA, 60 Hz frequency. Acute treatment: 60-minute session at first sign of migraine attack using higher frequency "ACUTE" program; can be used for up to two consecutive sessions (2 hours total). |
38.2% of patients achieved ≥50% reduction in monthly migraine days in episodic migraine. For chronic migraine, about 19% achieved significant reduction. For acute treatment, 29% reported complete relief after 1-hour session. |
Moderate Multiple controlled trials |
Tingling or burning sensations at application site, skin irritation, sleepiness; most side effects diminish with continued use |
|
Non-invasive Vagus Nerve Stimulation (nVNS) gammaCore Sapphire™ |
 |
Non-invasive Handheld device |
Delivers mild electrical stimulation to the cervical branch of the vagus nerve in the neck. Modulates pain pathways by affecting neurotransmitter release and inhibiting trigeminal nociception. | Prevention: Two 2-minute stimulations (one on each side) twice daily. Acute treatment: Two 2-minute stimulations concurrently with acute medication. |
10% of patients with chronic migraine achieved ≥50% reduction in headache days. Overall response rate across studies is approximately 31%. |
Moderate Randomized controlled trials |
Neck pain, muscle contractions at stimulation site, skin irritation, temporary dizziness; generally well-tolerated |
|
Remote Electrical Neuromodulation (REN) Nerivio® |
 |
Non-invasive Wearable device |
Stimulates peripheral nerves in the upper arm to activate conditioned pain modulation (CPM), a natural pain-relieving mechanism that inhibits pain signals via descending pathways. | Prevention: 45-minute sessions every other day. Acute treatment: 45-minute sessions at migraine onset. |
Meta-analysis of 12 studies (9,912 patients): 64% achieved pain reduction at 2h, 22% pain-free at 2h, 59% sustained pain relief at 24h, and 54% sustained pain-free at 24h. 51.6% achieved ≥50% reduction in headache days in prevention trials. |
High Systematic review & meta-analysis of 12 studies |
Meta-analysis showed only 0.4% of users experienced device-related adverse events. Most common: temporary arm/shoulder numbness, tingling, warmth sensation, mild muscle spasms; generally very well-tolerated with no serious adverse events reported |
|
Dual-channel External Trigeminal-Occipital Neurostimulation Relivion® |
 |
Non-invasive Wearable device |
Simultaneously stimulates trigeminal nerve branches (supraorbital, auriculotemporal) and occipital nerves. The dual-channel approach targets multiple pain pathways involved in migraine. | Acute treatment: 1-hour session at migraine onset. Prevention: Daily 20-40 minute sessions. |
46-60% of patients achieved ≥50% reduction in migraine days; approximately 3-day reduction in monthly migraine days. |
Moderate Growing clinical evidence base |
Localized tingling, scalp discomfort, temporary skin redness, muscle twitching; most patients adapt to sensations |
|
Single-pulse Transcranial Magnetic Stimulation (sTMS) sTMS mini™ (eNeura) |
 |
Non-invasive Handheld device |
Delivers brief magnetic pulses to the occipital cortex, primarily targeting migraine with aura. These pulses may inhibit cortical spreading depression and modulate hyperexcitable neurons. | Prevention: 4 pulses twice daily. Acute treatment: 3 pulses at onset, repeated up to 3 times if needed. |
46% of patients achieved ≥50% reduction in headache days; effective for both prevention and acute treatment, especially in migraine with aura. |
Moderate Clinical trials plus open-label data |
Mild scalp discomfort, temporary lightheadedness, tingling sensations, transient hearing changes |
| Repetitive Transcranial Magnetic Stimulation (rTMS) |  |
Non-invasive Clinical procedure |
Delivers repeated magnetic pulses to specific cortical targets (dorsolateral prefrontal cortex, primary motor cortex, frontal cortex) to modulate neuronal excitability and pain networks. | Multiple clinical sessions (typically 5-23) with various stimulation parameters; high-frequency (10-20 Hz) or low-frequency (≤1 Hz) protocols. | Up to 78.7% response rate reported for high-frequency stimulation; more effective when applied to left frontal cortex. |
Moderate Multiple controlled studies |
Scalp discomfort during sessions, post-treatment headache, transient dizziness, fatigue, mild neck pain |
| Transcranial Direct Current Stimulation (tDCS) |  |
Non-invasive Clinical procedure |
Applies low-intensity electrical current to various cortical targets (motor cortex, visual cortex, prefrontal cortex) to modulate neuronal excitability and normalize cortical activity patterns. | Typically 1-3 mA current for 20-30 minutes per session; daily or several times weekly for 1-5 months. | Up to 81.8% achieved ≥50% reduction in headache days or attack frequency, depending on stimulation parameters and target. |
Moderate Growing research base |
Tingling, itching, or burning sensations under electrodes, temporary fatigue, mild headache during initial sessions |
|
Occipital Nerve Stimulation (ONS) Various implantable systems |
 |
Invasive Surgical implant |
Surgical implantation of electrodes adjacent to greater and/or lesser occipital nerves, connected to an implanted pulse generator. Modulates nociceptive processing in the trigeminocervical complex. | Continuous or cyclic stimulation delivered via implanted electrodes; programming adjusted based on patient response. | Approximately 36.3% of patients achieved ≥50% reduction in headache frequency; reported reductions of 6-12 headache days per month. |
Moderate Several controlled trials |
Risk of infection, lead migration, battery depletion requiring replacement, hardware complications, implant site pain, muscle spasms |
| Deep Brain Stimulation (DBS) |  |
Invasive Neurosurgical procedure |
Electrodes surgically implanted in deep brain structures (hypothalamus, anterior thalamus, or subthalamic nucleus) connected to an implanted pulse generator. Modulates central pain networks. | Continuous stimulation following surgical implantation; reserved for extremely refractory cases after failure of all other treatments. | Limited to case reports of complete remission or significant reduction in migraine attacks; insufficient data for statistical analysis. |
Very Low Limited to case reports |
Serious risks including intracranial hemorrhage, infection, neurological deficits, hardware complications, and standard neurosurgical risks |
|
High-Frequency (10 kHz) Spinal Cord Stimulation (HF-10 SCS) Senza® System |
 |
Invasive Surgical implant |
Electrodes surgically implanted at the high cervical (C2-C3) spinal cord level, connected to an implanted pulse generator. High-frequency stimulation modulates pain signals via the dorsal columns. | Continuous high-frequency stimulation following surgical implantation; programming adjusted based on individual response. | 50-71% of patients achieved ≥50% reduction in headache frequency or pain intensity; mean pain reduction of approximately 60%. |
Low Promising early evidence |
Lead migration, infection, implant site pain, hardware-related complications, standard surgical risks; requires comprehensive evaluation |
References
- Tana C, Garcia-Azorin D, Raffaelli B, et al. Neuromodulation in Chronic Migraine: Evidence and Recommendations from the GRADE Framework. Advances in Therapy. 2025. DOI: 10.1007/s12325-025-03206-7
- Alokley A, ALNasser MN, Alabdulqader RA, et al. Effectiveness of low dose thyroxine in patients with subclinical hypothyroidism and migraine; systematic review and meta-analysis. BMC Neurology. 2025;25:198. DOI: 10.1186/s12883-025-04214-4
- Alnajjar AZ, Mustafa MMM, Abdelsalam OK, et al. Efficacy and safety of remote electrical neuromodulation in migraine: a comprehensive systematic review and meta-analysis. BMC Neurology. 2025;25:327. DOI: 10.1186/s12883-025-04291-5
- Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80(8):697-704.
- Silberstein SD, Calhoun AH, Lipton RB, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. 2016;87(5):529-38.
- Tepper SJ, Rabany L, Cowan RP, et al. Remote electrical neuromodulation for migraine prevention: a double-blind, randomized, placebo-controlled clinical trial. Headache. 2023;63(3):377-89.
- Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurology. 2010;9(4):373-80.
- Misra UK, Kalita J, Bhoi SK. High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebo-controlled study. Journal of Neurology. 2013;260(11):2793-801.
- Antal A, Kriener N, Lang N, et al. Cathodal transcranial direct current stimulation of the visual cortex in the prophylactic treatment of migraine. Cephalalgia. 2011;31(7):820-8.
- Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012;32(16):1165-79.
- Lendvai IS, Kinfe TM. Migraine improvement after anterior thalamic deep brain stimulation for drug-resistant idiopathic generalized seizure: a case report. Headache. 2017;57(6):964-6.
- Lambru G, Trimboli M, Palmisani S, et al. Safety and efficacy of cervical 10 kHz spinal cord stimulation in chronic refractory primary headaches: a retrospective case series. Journal of Headache and Pain. 2016;17(1):66.
Tue, Sep 08, 26
Botox for Chronic Migraine: What 479 Real-World Patients Show
A 479-patient real-world study of onabotulinumtoxinA for chronic migraine found a mean reduction of 5.9 monthly headache days, with 27.3% reaching the 50% response threshold and 41.6% shedding medication overuse....
Read MoreWed, Sep 02, 26
The New Migraine Prevention Guideline: What the AAN and AHS Recommend
The American Academy of Neurology and the American Headache Society have published a joint practice guideline on migraine prevention in adults: 17 recommendations and 52 statements. It names no single...
Read More
Thu, Aug 27, 26
Migraine Research News: The Best Place to Follow New Migraine Studies Daily
Migraine research moves every week and almost none of it reaches the people who have migraine. Today in Migraine Science is a free page, updated daily, that summarizes the newest...
Read More
Latest posts
Migraine science on Instagram
New research broken down in plain language, most days of the week.
Follow @cerebral_torque
